Article ID Journal Published Year Pages File Type
8733649 Critical Reviews in Oncology/Hematology 2018 9 Pages PDF
Abstract
Our study indicates that FOLFOX + panitumumab has the major probability to provide an improvement of survival with a good safety profile in patients with RAS WT mCRC with an added value from selection based on sidedness.
Related Topics
Health Sciences Medicine and Dentistry Hematology
Authors
, , , , , , , , , , ,